

ProvideGuidance: Orderin**©**OVID-19 Treatment for Nonhospitalized Patients

UI Health Care Providers can order IV monoclonal antibody or oral antiviral therapies for the treatment of COVID-19 in nonhospitalized patients starting on 6/28/2022. Pharmacists will also continue offering treatment to eligible patients until 7/15/2022.

Which COVID-19 treatment medications can providers order?

 Paxlovid (nirmatrelvir co-packaged with ritonavir), Lagevrio (molnupiravir), and monoclonal antibody treatment (i.e., bebtelovimab)

How do I evaluate and order COVID-19 treatment medications in Epic?

- The Epic SmartSet'UIHC:COVID OUTPATIENT THERAPY' has been created to aid with e-prescribing
- The Epic SmartPhrase '.COVIDTREATMENT' has been created to support treatment selection and patient education Which UI Pharmacies will have Paxlovid and molnupiravir in stock?
- · Discharge, Iowa River Landing, and River Crossing ambulatory pharmacies

Can I e-prescribe Paxlovid and molnupiravir to an external pharmacy?

• Yes, if the local pharmacy has been allocated drug by the lowa Department of Public Health (drug locator website: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/)

What is the process to administer monoclonal antibody treatment to a patient?

- Provider orders monoclonal antibody for a patient utilizing the Epic SmartSet 'UIHC:COVID OUTPATIENT THERAPY' (antibody cannot be ordered within an Epic telephone encounter)
- Drug order auto-routes to a work gueue for PAC team members to schedule the patient appointment
- IV monoclonal antibody treatment is administered to the patient at the IRL Infusion Suite on weekdays
- Appointment availability and timing from symptom onset may be a limiting factor
 What is the preferred order for selecting treatment? (Refer to guidance pathway diagram on the following page)
- 1st choice: Paxlovid (nirmatrelvir-ritonavir)
 - 88% relative risk reduction in COVID-related hospitalization or death compared to placebo in unvaccinated subjects with risk factors for severe disease
- · 2nd choice: monoclonal antibody if Paxlovid is not available or clinically appropriate
 - Bebtelovmiab demonstrated viral load reduction and symptom improvement compared to placebo
- · 3rd choice: molnupiravir if Paxlovid and monoclonal antibody are not available or clinically appropriate
 - 30% relative risk reduction in hospitalization or death compared to placebo in unvaccinated subjects with risk factors for severe disease



Changing Medicine. Changing Lives.®

Patients ≥12 years and ≥40 kg Patient must meet at least 1 risk factor for progression to severe disease (see more Medication orders can be found within the information here): Patient diagnosed with mild-**UIHC:COVID Outpatient Therapies order set** -Age ≥40 years moderate COVID-19 -Cancer -Cerebrovascular disease -Chronic kidney disease -Chronic liver diseases -Chronic lung diseases Cvstic fibrosis Patient should be Assess for EUA -Dementia criteria for COVID -Diabetes mellitus, type 1 and 2 treated with **Ineligible** -Disabilities (ADHD, developmental, etc) supportive at-home outpatient -Heart conditions therapeutics Immunosuppressive disease or treatment -Mental health disorders -Overweight or obesity (BMI ≥25 kg/m2 (or ≥85th Eligible Decision against pursuit of therapy percentile for age in pediatrics) -Physical inactivity -Pregnancy and recent pregnancy -Sickle cell disease or thalassemia Prescriber ensures -Smoking, current and former Paxlovid provided to up-to-date home Assess for suitability of -Solid organ or hematopoietic cell transplantation patient (dose based med list to validate therapeutics based on clinical -Substance use disorders on renal function); lack of high-risk assessment of risk factors and -Tuberculosis fact sheet provided shared decision-making **Paxlovid** Can use Epic order: Follow-up ILI Respiratory Telemedicine Visit (FOL159) to request video visit Patient accepts Decision to pursue therapy with ILI Telemedicine provider to discuss antiviral treatment options with patient Prescriber provides Assess for education and -Eligible eligibility for Exclusion criteria: enters order using Paxlovid -Symptom onset beyond 5 days prior order set -eGFR <30 ml/min/1.73m2 -High-risk drug-drug interaction (see list) -Inability to tolerate oral administration Patient is scheduled -History of allergy to either nirmatrelvir or for mAB infusion; Not eligible for Paxlovid ritonavir fact sheet provided -Uncontrolled HIV -Patient declines Paxlovid--Age <12 years -Weight <40 kg Prescriber providers education and Assess for eligibility for Patient accepts enters referral to IRL <-Eligible Exclusion criteria: -Symptom onset beyond 7 days from scheduled infusion center using mAB) infusion order set -History of allergy to specific mAB -Age <12 years -Weight <40 kg Fact sheet Not eligible for mAB **Infusions are scheduled at IRL Monday through Friday (schedules fluctuate)** provided and -Patient declines mABmolnupiravir provided to patient Prescriber provides Consider Exclusion criteria: education and assessing for -Symptom onset beyond 5 days prior Patient accepts -Eligible enters order using eligibility for -Age <18 years order set molnupiravir -History of allergy to molnupiravir -Pregnancy (men and women of childbearing age must agree to contraceptive use) Patient declines molnupiravir **NOTE: molnupiravir efficacy is reduced Ineligible and/or election to not pursue molnupiravir compared to other therapies**

Outpatient COVID Therapeutics Pathway

Page 1 June 22, 2022